MicroPort Product Receives Registration Certificate in South Korea

On October 31, Jive™ PTCA Balloon Dilatation Catheter received registration certificate from Ministry of Food and Drug Safety of South Korea, which is the first time for MicroPort products to gain such an approval in this country.

Interpretation of China’s Medical Device Management Regulations

On October 16, Quality Department of MicroPort Lifesciences (Shanghai) Co (“MicroPort Lifesciences”) attended Beijing Medical Device Industry Forum organized by Beijing Pharmaceutical Profession Association. During the conference, experts interpreted the latest edition of China’s Medical Device Management Regulations, which would facilitate our work in the future.
**MicroPort EP Attends Heart Rhythm Forum**

From October 31 to November 2, Shanghai Heart Rhythm Forum was held in Shanghai. Shanghai MicroPort EP MedTech Co (“MicroPort EP”) attended the meeting to promote our products.

---

**MicroPort Holds OIAA Meeting**

From October 30 to October 31, International Business Department of Shanghai MicroPort Medical (Group) Co (“MicroPort”) organized Otsuka International Asia Arab Division (“OIAA”) Meeting to enhance communications with Asian distributors. Participated distributors from Philippines, Thailand, Pakistan and Indonesia were invited to attend training programs on Firehawk® and visit MicroPort EP.
MicroPort Endovascular
Attends Vascular Surgery Conference
From October 31 to November 1, the first Academic Conference of Vascular Surgery Society of Hebei Medical Association was held in Shijiazhuang, Hebei Province. MicroPort Endovascular (Shanghai) Co (“MicroPort Endovascular”) attended the meeting and introduced our new products to participants.

MicroPort Endovascular
Introduces Products in Cardiovascular Forum
From October 31 to November 2, the 4th Shenzhen Cardiovascular Forum was held in Shenzhen, Guangdong Province. MicroPort Endovascular attended the meeting. Professor Sihong Zheng from Beijing Anzhen Hospital presented the clinical efficacy of our stent graft in surgical operation, which was well received by attendees.

MicroPort Endovascular
Attends Peripheral Vascular Disease Conference
From November 6 to November 8, the first Academic Annual Meeting of the Special Committee of Peripheral Vascular Disease of Chinese Society of MicroCirculation was held in Beijing. More than 200 professionals of vascular surgery and interventional treatment were invited to attend the congress. MicroPort Endovascular participated and promoted its products.
MicroPort Hosts AIIF

From November 3 to November 7, MicroPort organized Aortic Intervention International Forum ("AIIF") which focused on aortic products of MicroPort Endovascular. A total of 36 surgeons and distributor from South America attended the meeting. MicroPort Endovascular introduced products that have been launched (Hercules™ T/B and Aegis™), products that are about to launch (Hercules Low Profile) and products that are under clinical research (Castor) to participants.

MicroPort Lifesciences Attends Diabetes Meeting

From November 5 to November 8, 18th Scientific Meeting of the Chinese Diabetes Society was held in Guangzhou, Guangdong Province. MicroPort Lifesciences attended the conference and learnt the latest industry trend and competitors’ actions.
MicroPort NeuroTech Attends Neuro-intervention Meeting

On November 9, Neuro-intervention Meeting of Shandong Stroke Association was held in Jinan, Shandong Province. MicroPort NeuroTech (Shanghai) Co ("MicroPort NeuroTech") attended and hosted a satellite meeting to introduce our neurovascular devices APOLLO Intracranial Stent System, WILLIS Intracranial Stent Graft System and Aether™ Distal Protective Device to people in attendance.
MicroPort NeuroTech Attends OCIN

MicroPort NeuroTech attended the 14th Oriental Conference of Interventional Neuroradiology ("OCIN") that was held from October 31 to November 2 in Shanghai, to promote our neurovascular devices.

During the conference, MicroPort NeuroTech were present with a booth that focused on our products such as WILLIS® Intracranial Stent Graft System and Tubridge® Vascular Reconstruction Device. We also arranged a variety of activities, including WILLIS® surgery simulation and live broadcasted surgery of WILLIS®, to enable participants to gain hands-on experience and in-depth knowledge on the product. Meanwhile, Professor Qinghai Huang with Shanghai-based Changhai Hospital and Professor Donglei Song from Shanghai Neuromedical Center were invited to present in details the clinical applications and efficacy of WILLIS® and Tubridge® with thorough and reliable clinical data.

In OCIN, WILLIS® was highly recognized by healthcare professionals in attendance. "As the first neurovascular stent graft in the world, WILLIS® shows our (China's) determination for innovation," said Professor Jianmin Liu from Changhai Hospital. Also, Professor Weijian Jiang of the Second Artillery General Hospital of Chinese People's Liberation Army expressed his praise on WILLIS®'s better-than-expected performances in some difficult cases.

To further optimize our devices, MicroPort NeuroTech later on invited healthcare professionals who attended OCIN to visit our product showrooms and manufacturing plants, and organized a face-to-face discussion with them on how to improve the future devices in terms of R&D, design and production.
"We hope to continue working with doctors to get ideas and inspirations to develop more high-quality products so as to better serve them and patients," said Bo Peng, Chief Marketing Officer of MicroPort Scientific Corporation.
MicroPort EP Promotes Columbus™ in Argentina Congress

From November 14 to November 15, Sociede Latin American Estimulation Cardiac Electrophysiology (“SOLAECE”) was held in Buenos Aires of Argentina. MicroPort EP attended the congress to promote our Columbus™ 3D EP Navigation System to people in attendance. Dr. Manuel Patete, an electrophysiologist from South America, was invited to present the efficacy of the device.

MicroPort Endovascular Attends VIVA

From November 4 to November 7, MicroPort Endovascular attended Vascular Interventional Advances (“VIVA”) that was held in Las Vegas of the US. We took this opportunity to enhance communications with executives of potential business partners in hope to pave the way for future cooperation.
MicroPort Attends World Forum for Medicine in German

From November 12 to November 15, MicroPort took part in MEDICA that was held in Germany. MEDICA is a world forum for medicine and one of the biggest exhibitions for medical devices. MicroPort promoted our electrophysiological devices as well as products that have gained CE certificate. We had meetings with clients from Russia, the Netherlands, Greece, Vietnam and Columbia, and reached tentative agreements with some of them.

MicroPort Attends Cardiovascular Seminar

From November 14 to November 16, Cardiovascular Emergency Treatment Seminar was held in Shijiazhuang, Hebei Province. Professor Xuming Zhang of Peking University People's Hospital presented the advantages of Castor Thoracic Branch Stent-Graft System, which was well received by participants.
MicroPort Endovascular Attends 2014 VEITH Symposium

From November 18 to November 22, the 2014 VEITH Symposium was held in New York. MicroPort Endovascular attended the five-day conference and learnt the most current information about new developments in clinical practice and relevant research.

MicroPort Attends Heart Forum in Shanghai

From November 21 to November 23, MicroPort attends 2014 Jiaotong University Heart Forum that was held in Shanghai. During the event, MicroPort hosted a satellite meeting focused on Firehawk® Rapamycin Target Eluting Coronary Stent. Several professors from influential hospitals in China were invited to introduce in depth five features of Firehawk® and release the latest research results of TARGET products to the audience.
MicroPort Promotes Awareness of Heart Attack in Beijing Community

In partnership with Beijing-based Chinese PLA General Hospital and Beijing Haidian District Government, MicroPort launched a community activities program to promote public knowledge and awareness of heart attack on November 13 in Beijing.

The community campaign aims to raise awareness about heart attack and educate the public about the importance to get quick treatment. Through the program, MicroPort hopes to work with hospitals to help lower the death rate of heart attack in local community.

Professor Yundai Chen and Qinhua Jin with Chinese PLA General Hospital were invited to engaged in a range of training and lectures to help the community learn about heart attack symptoms, first-aid treatments and how to get immediate treatment from green channels of hospitals’ chest pain centers – several hospitals in China now have opened green channels to ensure patients with chest pain can get prompt treatment.

In China, an increasingly more people are suffering from heart attack, according to experts. It is estimated that there are about 500,000 new cases every year and in total more than 2 million patients suffer from heart attack in China. More alarmingly, about two thirds of patients suffering from acute heart attack died because they were not treated promptly. According to industry surveys, a patient could be left untreated for five to eight hours in some local hospitals.
Dongguan Kewei Participates Cardiovascular Meeting

On November 20, the 14th Annual Scientific Meeting of Chinese Society for Thoracic and Cardiovascular Surgery ("CSTCS") was held in Chengdu, Sichuan Province. MicroPort’s subsidiary Dongguan Kewei Medical Co ("Dongguan Kewei") participated in the meeting to learn up-to-date information of the cardiovascular industry and to introduce our surgical management products to more surgeons and distributors.
MicroPort Awarded Recognition from Government Institutions

On November 5, MicroPort was once again recognized as one of the key high-tech enterprises under the Torch Program of Torch High Technology Industry Development Center of Ministry of Science & Technology. The Torch Program was designed to support the growth of a group of promising high-tech enterprises in hope that they would eventually drive the development of the whole industry. It is a great honor for MicroPort to be selected as one of them.

Annual Meeting of the Japanese Hip Society

The 41st Annual Meeting of the Japanese Hip Society was held in Tokyo from October 31 to November 1. More than 1,700 people attended the meeting and 77 booths were displayed. The booth of MicroPort Orthopedics attracted many attentions and surgeons came to inquire about our products.
Annual Meeting of Japanese Society for Clinical Biomechanics

The 41st Annual Meeting of the Japanese Society for Clinical Biomechanics was held in Nara prefecture on November 21 and November 22. The Marketing and Clinical Affair Department of MicroPort Orthopedics Japan attended to exchange latest information.
PROFEMUR® Classic Z Hip Stem Awarded CFDA Registration Certificate

PROFEMUR® Classic Z Hip Stem, a hip device developed by MicroPort Orthopedics, was recently awarded registration certificate from China Food and Drug Administration ("CFDA").

The device is designed to cure hip pain and hip functional disabilities caused by hip diseases such as osteoarthritis, rheumatic arthritis and femoral neck fracture. PROFEMUR® Classic Z Hip Stem shares the same design concept with PROFEMUR® Z modular stem which was first launched in 1985 and has been proved safe and effective with its over 29 years' excellent clinical history.

The PROFEMUR® Classic Z Hip Stem is a dual tapered, titanium-alloy hip implant with a rectangular cross-section. The tapered, rectangular cross-section provides proximal fixation and rotational stability. With two neck angels in two lengths, the product offers surgeons a variety of options to meet range of anatomical needs.

"The product is currently sold in many countries across the globe, and now with the CFDA registration certificate, we have high expectations on its sales performance in the China market," said Simon Chen, Vice General Manager of Marketing of Shanghai MicroPort Orthopedics Co ("MicroPort Orthopedics Shanghai").
SOFCOT Congress in France

The 2014 SOFCOT (The French Society of Orthopedic and Trauma Surgery) Congress was held in Paris from November 10 to November 13.

MicroPort Orthopedics was present with its international marketing booth which generated a lot of interest from the participants. The focus was on the medial pivot strategy.
Medical Education: Total Joint Arthroplasty

In support of our global commitment to educate healthcare providers, MicroPort Orthopedics Shanghai and Shanghai Tenth People’s Hospital recently hosted a Medical Education event that focused on surgeon training in advanced surgical techniques and treatment options for total joint arthroplasty. It is our first cadaver training on SUPERPATH* tissue-sparing surgical techniques and ADVANCE* Medial-Pivok Knee system in Asia. Several healthcare professionals from China and Japan attended the event.

The training was led by a faculty specializing SUPERPATH* tissue-sparing surgical techniques and ADVANCE* Medial-Pivok Knee. Dr. Jimmy Chow, a hip and knee replacement surgeon at US-based St. Luke’s Medical Center and Professor Elvis Grandic from Florida of the US explained SUPERPATH* techniques in depth and Professor You Wang from the Ninth People’s Hospital shared the advantages of ADVANCE* Knee system. We also arranged operation practices for participants to gain hands-on experience on both hip and knee treatments.
MicroPort Orthopedics Attends the 9th COA Congress

MicroPort Orthopedics Shanghai, a wholly owned subsidiary of MicroPort, attended the Ninth Chinese Orthopaedic Association ("COA") that was held in Beijing from November 20 to November 23, to further promote its orthopedic products to participants.

On the first day of the congress, Dr. Jimmy Chow, a hip and knee replacement surgeon at St. Luke's Medical Center located in Phoenix of the US, was invited to deliver a speech on SUPERPATH® tissue-sparing surgical techniques as well as its clinical outcome in the past six years.

Dr. Chow said, SUPERPATH® is a revolutionary surgical technique as it is designed to precisely reconstruct the hip without cutting critical tendons and stretching or traumatizing muscles that are important to hip function. With SUPERPATH®, there is no surgical dislocation of the hip and the integrity of the capsule is completely preserved. Because of the elimination of damage to the important structures during reconstruction, patients typically have a short hospital stay.
According to Dr. Chow citing analysis results based on 1,021 surgical cases using SUPERPATH* dated from 2008, about 97 percent of the patients left the hospital the same day as their surgery and 60 percent of them managed to get back on their feet within four hours after the surgery.

On November 22, MicroPort Orthopedics Shanghai hosted a satellite meeting focused on the surgical techniques and clinical efficacy of SUPERPATH* Micro-posterior total hip replacement and ADVANCE* Medial-Pivot Knee system, which attracted more than 500 orthopedic professionals.

"For patients, MicroPort Orthopedics’ ADVANCE* Medial-Pivot Knee feels better as it more closely imitates the natural knee. For surgeons, it is easier for a beginner of total knee replacement to implant," said Professor Tiebin Qu from Capital Medical University.

"MicroPort Orthopedics is committed to bringing a rapidly increasing product offering to patients and surgeons. We’ll also continue to launch medical education events to further promote the academic levels of China’s orthopedic industry," said Shengqiang Wang, General Manager of MicroPort Orthopedics Shanghai and Vice President of MicroPort’s Orthopedic Business in China.
For more information, please contact:

Hongbin Sun  
Chief Financial Officer  
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)  
Tel: (86)(21) 38954600  
Email: ir@micoport.com

Xun You  
Board Secretary  
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)  
Tel: (86)(21) 38954600  
Email: ir@micoport.com